Dr MBA - MediciNova Chief Officer
| MNOV Stock | USD 2.00 0.05 2.56% |
Insider
Dr MBA is Chief Officer of MediciNova
| Age | 59 |
| Address | 4275 Executive Square, La Jolla, CA, United States, 92037 |
| Phone | 858 373 1500 |
| Web | https://www.medicinova.com |
MediciNova Management Efficiency
The company has return on total asset (ROA) of (0.0951) % which means that it has lost $0.0951 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1332) %, meaning that it created substantial loss on money invested by shareholders. MediciNova's management efficiency ratios could be used to measure how well MediciNova manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, MediciNova's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 4.8 M in 2024, whereas Other Assets are likely to drop slightly above 101.4 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| MD MBA | Rezolute | N/A | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| MBA BS | AN2 Therapeutics | 49 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Morgan Conn | Pharvaris BV | 55 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Jennifer Cormier | PepGen | N/A | |
| Niels Svenstrup | PepGen | 54 | |
| Peng MD | Pharvaris BV | 46 | |
| RA MSc | Pharvaris BV | 43 | |
| Man MBA | Adagene | 47 | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
| Deepika PharmD | Pmv Pharmaceuticals | 47 | |
| Michael Gait | PepGen | N/A | |
| BS CMAR | Champions Oncology | N/A | |
| Anne Lesage | Pharvaris BV | 63 | |
| David Mack | Pmv Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0951 |
MediciNova Leadership Team
Elected by the shareholders, the MediciNova's board of directors comprises two types of representatives: MediciNova inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MediciNova. The board's role is to monitor MediciNova's management team and ensure that shareholders' interests are well served. MediciNova's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MediciNova's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason CPA, CFO Officer | ||
| Dr MBA, Chief Officer | ||
| Yuichi MD, President, CoFounder | ||
| MD MPH, Chief Director | ||
| John CPA, Controller |
MediciNova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MediciNova a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0951 | ||||
| Operating Margin | (9.82) % | ||||
| Current Valuation | 53.94 M | ||||
| Shares Outstanding | 49.05 M | ||||
| Shares Owned By Insiders | 2.98 % | ||||
| Shares Owned By Institutions | 21.30 % | ||||
| Number Of Shares Shorted | 182.2 K | ||||
| Price To Earning | (24.69) X | ||||
| Price To Book | 1.71 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.